Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kyverna Therapeutics, Inc.

NASDAQ: KYTX · Life Sciences · 3 alerts · CIK 1994702

Share price
$4.76Close, Nov 16
Market cap
$301M
Shares outstanding
63.22MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kyverna Therapeutics, Inc. filings on SEC EDGAR ↗

8:05 AM ET 10-Q
Financial Results

Kyverna Therapeutics Q3 2026 Results: Net Loss of $41.9M, Loss Widens

Kyverna Therapeutics reported a net loss of $119.99 million for the nine months ended September 30, 2026, compared to $123.50 million in the prior year period. The company's cash and marketable securities position decreased to $170.57 million as of September 30, 2026, down from $279.25 million at the end of 2025, primarily due to ongoing research and development expenses.

Key figure
Net loss $41.9M
8:02 AM ET 8-K
Financial Results

Kyverna Therapeutics Financial Results

Kyverna Therapeutics reported Q3 2026 financial results and announced the completion of its rolling BLA submission to the FDA for miv-cel in Stiff Person Syndrome (SPS). The company ended the quarter with $312.4 million in cash and equivalents, which it expects will fund operations into 2028 as it prepares for a potential commercial launch in 2027.

Term
Q3 2026

“Kyverna is very proud to submit the first BLA for a CAR T-cell therapy in autoimmune disease, paving the way for a potential new standard of care with a single dose, designed to reset the immune system and free patients from lifelong disease and chronic immunotherapies.”

Warner Biddle, Chief Executive Officer of Kyverna

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.